16948-10-0

Basic information

• Product Name: Boc-DL-3-Aminoisobutyric acid
• Synonyms: Boc-DL-3-Aminoisobutyric acid;3-(tert-butoxycarbonylamino)-2-methylpropanoic acid;REF DUPL: Boc-DL-3-Aminoisobutyric acid;Boc-DL-3-AMinoisobutyric acid Boc-DL-3-AMinoisobutyric acid;Propanoic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-2-Methyl-, (±)-;3-(BOC-AMINO)-2-METHYLPROPANOIC ACID;3-(tert-butoxycarbonyl)-2-methylpropanoic acid
• CAS NO: 16948-10-0
• Molecular Formula: C₉H₁₇NO₄
• Molecular Weight: 203.23558
• Mol File: 16948-10-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: 89-90℃ (ethyl ether pentane )
• Boiling Point: 339.5°C at 760 mmHg
• Flash Point: 159.1°C
• Appearance: /
• Density: 1.101±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 1.69E-05mmHg at 25°C
• Refractive Index: 1.46
• Storage Temp.: 2-8°C
• PKA: 4.53±0.10(Predicted)
• CAS DataBase Reference: Boc-DL-3-Aminoisobutyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-DL-3-Aminoisobutyric acid(16948-10-0)
• EPA Substance Registry System: Boc-DL-3-Aminoisobutyric acid(16948-10-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 16948-10-0(Hazardous Substances Data)

Usage

General Description

Boc-DL-3-Aminoisobutyric acid is a synthetic compound that consists of a Boc (tert-butoxycarbonyl) protecting group, a DL-3-aminoisobutyric acid core, and a carboxylic acid functional group. The Boc group serves to protect the amine functionality of the molecule, while the DL-3-aminoisobutyric acid core is a non-proteinogenic amino acid that contains an isobutyl side chain. This chemical is commonly used in peptide synthesis as a building block for the creation of complex peptides. Its unique structure and stability make it a valuable tool in the field of medicinal chemistry and drug development.

InChI:InChI=1/C9H17NO4/c1-6(7(11)12)5-10-8(13)14-9(2,3)4/h6H,5H2,1-4H3,(H,10,13)(H,11,12)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1572-99-2 ethyl 2-cyanopropionate 
• 162465-19-2 (2S,2'R)-2-<<3'<(tert-butoxycarbonyl)amino>-2'-methylpropanoyl>oxy>-4-methylpentanoic acid 
• 10569-72-9 DL-3-aminoisobutyric acid 
• 16965-08-5 1,1-dimethylethyl 2,4,5-trichlorophenyl carbonate 

Downstream Products

• 357610-23-2 benzyl 2-methyl-3-(tert-butyloxycarbonylamino)propionate 
• 357610-32-3 N-Boc-α-methyl-β-alanine N-carboxyanhydride 
• 357610-26-5 benzyl 2-methyl-3-(di-tert-butyloxycarbonylamino)propionate 
• 312493-43-9 (R)-(+)-α-methylbenzylammonium salt of (2R)-3-tert-butoxycarbonylamino-2-methylpropionic acid 
• 1092069-25-4 C₂₇H₃₄Cl₂N₄O₄ 
• 942425-69-6 5-Methyl-2,4-dioxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1427185-32-7 tert-butyl (3-((4-cyanobenzyl)amino)-2-methyl-3-oxopropyl)carbamate 

Relevant articles and documents

Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines

The present invention relates to an amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines. In particular, the present invention relates to an amine compound for inhibiting a semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, or a pharmaceutically acceptable salt thereof, a stereoisomer or an/a E/Z isomer, further relates to a pharmaceutical composition containing the amine compound. The invention further relates to the application of the amine compound and the pharmaceutical composition in manufacture of the medicines for treatment of inflammation, inflammation-related diseases and immune diseases.

Direct C-H alkylation of naphthoquinones with amino acids through a revisited Kochi-Anderson radical decarboxylation: Trends in reactivity and applications

In our ongoing research program into the discovery of new anticancer drugs, we were interested in the preparation of naphthoquinone scaffolds bearing aminoalkyl side-chains. Following this aim, we revisited the Kochi-Anderson radical decarboxylation of amino acids in order to set up a versatile route to the direct functionalization of naphthoquinones. The best reaction conditions were applied to a selected series of compounds in a systematic methodological study which allowed us to establish important trends in reactivity. We found that α-substituted β-amino acids were the most suitable substrates for the radical addition. In contrast, α-amino acids gave modest results. The influence of the amine protecting groups on the reaction outcome has also been studied. This practical procedure allows the introduction of various unsymmetrical moieties, including orthogonally protected linear aminoalkyl chains or chiral dipeptidic chains, and opens the door to a wide scope of easily accessible chemical diversity.

PROKINETICIN RECEPTOR ANTAGONISTS AND USES THEREOF

Contemplated compounds, compositions, and methods of prokineticin antagonists are presented where a prokineticin antagonist is used in the treatment and prevention of various conditions and disorders, and especially type II diabetes.